The Global Health Body Issues Alert Over Severe Shortage of Obesity Injections
Fewer than a tenth of patients eligible to benefit from obesity jabs such as Wegovy can access them, caution the WHO as it issues its initial recommendations on the medications.
Considering in excess of 1,000,000,000 individuals worldwide now living with obesity, it is calling for increased and just availability to this class of drugs.
Based on forecasts, over two billion will be living with obesity by 2030 without intervention.
"Our new guidance affirms that excess weight is a long-term condition that can be managed with thorough and ongoing support," said WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are significant hurdles to universal availability to the injections that can aid individuals in losing considerable body mass, says the agency.
Skinny Jab Supply Crisis
Despite the current best projected case, the manufacturing of such drugs would only suffice for about 100 million people – under 10% of eligible patients, according to the WHO.
The advice urges nations and manufacturers to widen availability, by approaches like patent sharing.
The intellectual property rights on semaglutide – the primary component of Novo Nordisk's Wegovy – is due to expire in several countries in 2026.
The Way Obesity Jabs Operate
These medications replicate a biological compound to slow digestion, curb appetite and enhance feelings of fullness so users eat less.
Patients commonly see weight reduction in the initial weeks of beginning the regular doses.
Studies suggests patients may regain a significant portion after a year of discontinuing the drug, as their normal appetite return.
To be carrying excess weight elevates your risk for experiencing health problems, including type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.
Excess weight affects people in every country and was responsible for millions of fatalities worldwide in 2024, according to the health agency.
